http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022257253-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6a6f422b091ba12ea61d4adbf1b0e8e |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce1fc5438a4758a14373d2af28859fde http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45eb9c9f227e36d668b138360303631b |
publicationDate | 2022-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2022257253-A1 |
titleOfInvention | Use of ginsenoside rg2 in preparation of drug for treating myelosuppression and drug containing ginsenoside rg2 |
abstract | The use of ginsenoside Rg2 in the preparation of a drug for treating myelosuppression and a drug containing ginsenoside Rg2. When chemotherapy causes myelosuppression, the use of ginsenoside Rg2 can promote the recovery of the ingredients of bone marrow cells, increase the number of bone marrow nucleated cells, remarkably increase the number of granulocyte-monocyte colony forming units and pre-B colony forming units in bone marrow, and promote the proliferation of granulocyte-monocyte and pre-B hematopoietic progenitor cells, which indicates that the ginsenoside Rg2 has the effect of promoting medullary hematopoiesis. |
priorityDate | 2021-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.